. "Humans and other mammals"@en . . "Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours. "@en . . . "Chlorpropamid"@en . . . "4-chloro-N-((Propylamino)carbonyl)benzenesulfonamide"@en . . . . . . . "IPN-RAT LD₅₀ 580 mg/kg"@en . "80-90% of a single oral dose is excreted in the urine as unchaged drug and metabolites within 96 hours. "@en . . "Food reduces the rate of absorption."@en . "4-chloro-N-[(Propylamino)carbonyl]benzenesulfonamide"@en . . . . "1-(P-Chlorobenzenesulfonyl)-3-propylurea"@en . . "approved"@en . "Readily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration. "@en . . . . . . . "For treatment of NIDDM in conjunction with diet and exercise. "@en . . . . . . "N-(P-Chlorobenzenesulfonyl)-n'-propylurea"@en . . . . . . "Chlorpropamidum"@en . "94-20-2"@en . . . . . . . . . . . . "Chlorpropamide"@en . "Chlorpropamide"@en . . . . . . . "Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin."@en . "N-Propyl-n'-P-chlorophenylsulfonylcarbamide"@en . . "1-(P-Chlorophenylsulfonyl)-3-propylurea"@en . . " "@en . . . . . . . . . . . . . . . . "N-Propyl-n'-(P-chlorobenzenesulfonyl)urea"@en . . . . . . "Avoid alcohol."@en . . . . . . . . . . . . . "N-(4-Chlorophenylsulfonyl)-n'-propylurea"@en . . . . "McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co., Inc."@en . . "Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating \u03B2 cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic \u03B2 cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia. "@en . "1-Propyl-3-(P-chlorobenzenesulfonyl)urea"@en . "Clorpropamida"@en . "Take 30 minutes before meal."@en . "Highly bound to plasma proteins."@en . . . . .